We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
INmune Bio Inc | NASDAQ:INMB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.36 | 11.07 | 12.13 | 0 | 09:00:00 |
Q2 2022 and Recent Corporate Highlights
DN-TNF Platform Highlights (XPro™ and INB03):
INKmune™ Platform:
Upcoming Milestones:
“In April, we announced the dosing of our first patient treated with XPro™1595 in the treatment of neuroinflammation as a cause of mild Alzheimer’s disease (AD) in Phase II clinical trial, AD02,” stated RJ Tesi, M.D., CEO of INmune Bio. “The trial is a blinded, randomized, placebo-controlled multicenter study in Australia, in Canada and in the United States. Although the trial in the United States is currently on hold pending conclusion of the FDA’s manufacturing inquiry, we continue to enroll patients in Australia where the trial is proceeding as planned. Additionally, our plan to launch additional blinded, randomized, placebo-controlled Phase II trials in patients with mild cognitive impairment (MCI) and TRD will occur after the clinical hold is lifted.
“Our INKmune™ platform continues to make positive strides. We are actively expanding the INKmune program towards the treatment of solid tumors. INKmune primed NK cells have unique biologic characteristics that should make the therapy effective in solid tumors,” concluded Dr. Tesi.
Financial Results for the Quarter Ended June 30, 2022:
Net loss attributable to common stockholders for the quarter ended June 30, 2022 was approximately $6.8 million, compared to approximately $6.7 million for the quarter ended June 30, 2021.
Research and development expense totaled approximately $4.2 million for the recent quarter compared to approximately $4.5 million during the quarter ended June 30, 2021.
General and administrative expense was approximately $2.2 million for the quarter compared to approximately $2.1 million during the quarter ended June 30, 2021.
Other expense was approximately $0.5 million for the quarter ended June 30, 2022 compared to approximately $ 0.1 million during the quarter ended June 30, 2021.
As of June 30, 2022, the Company had cash and cash equivalents of approximately $61.2 million. As of August 3, 2022, the Company had approximately 17.9 million common shares outstanding.
Earnings Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: August 3, 2022Time: 4:30 PM Eastern TimeParticipant Dial-in: 1-877-407-0784Participant Dial-in (international): 1-201-689-8560Conference ID: 13728540
A live audio webcast of the call can be accessed using this link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=Z4P1Gioe
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 10, 2022 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13728540.
About XPro™
XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.
About INKmune™
INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals akin to treatment with at least three cytokines in combination. INKmune™ is stable at -80oC and is delivered by a simple IV infusion. The INKmune:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720DMoss@INmuneBio.com
Investor Contact: Jason NelsonCore IR(516) 842-9614 x-823
The following tables summarize our results of operations for the periods indicated:
INMUNE BIO, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(In thousands, except share and per share amounts) | ||||||||
(Unaudited) | ||||||||
June 30,2022 | December 31,2021 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 61,213 | $ | 74,810 | ||||
Research and development tax credit receivable | 4,926 | 4,913 | ||||||
Other tax receivable | 134 | 591 | ||||||
Prepaid expenses | 4,222 | 2,278 | ||||||
Prepaid expenses – related party | 51 | 14 | ||||||
TOTAL CURRENT ASSETS | 70,546 | 82,606 | ||||||
Operating lease – right of use asset | 650 | 726 | ||||||
Other assets | 99 | 99 | ||||||
Acquired in-process research and development intangible assets | 16,514 | 16,514 | ||||||
TOTAL ASSETS | $ | 87,809 | $ | 99,945 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Accounts payable and accrued liabilities | $ | 1,687 | $ | 3,733 | ||||
Accounts payable and accrued liabilities – related parties | 9 | 80 | ||||||
Deferred liabilities | 476 | 474 | ||||||
Operating lease, current liabilities | 113 | 72 | ||||||
TOTAL CURRENT LIABILITIES | 2,285 | 4,359 | ||||||
Long-term debt, less debt discount | 14,571 | 14,458 | ||||||
Long-term operating lease liabilities | 645 | 704 | ||||||
Accrued liability – long-term | 375 | 199 | ||||||
TOTAL LIABILITIES | 17,876 | 19,720 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
STOCKHOLDERS’ EQUITY | ||||||||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding | - | - | ||||||
Common stock, $0.001 par value, 200,000,000 shares authorized, 17,945,995 and 17,843,303 shares issued and outstanding, respectively | 18 | 18 | ||||||
Additional paid-in capital | 148,072 | 143,921 | ||||||
Accumulated other comprehensive (loss) income | (701 | ) | 1 | |||||
Accumulated deficit | (77,456 | ) | (63,715 | ) | ||||
TOTAL STOCKHOLDERS’ EQUITY | 69,933 | 80,225 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 87,809 | $ | 99,945 | ||||
INMUNE BIO, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
FOR THE QUARTERS ENDED JUNE 30, 2022 AND 2021 | ||||||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
For the Three Months EndedJune 30, | For the Six Months EndedJune 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
REVENUE | $ | 16 | $ | - | $ | 179 | $ | 4 | ||||||||
OPERATING EXPENSES | ||||||||||||||||
General and administrative | 2,215 | 2,090 | 4,547 | 4,151 | ||||||||||||
Research and development | 4,189 | 4,464 | 8,498 | 6,955 | ||||||||||||
Total operating expenses | 6,404 | 6,554 | 13,045 | 11,106 | ||||||||||||
LOSS FROM OPERATIONS | (6,388 | ) | (6,554 | ) | (12,866 | ) | (11,102 | ) | ||||||||
OTHER EXPENSE | (450 | ) | (101 | ) | (875 | ) | (109 | ) | ||||||||
NET LOSS | $ | (6,838 | ) | $ | (6,655 | ) | $ | (13,741 | ) | $ | (11,211 | ) | ||||
Net loss per common share – basic and diluted | $ | (0.38 | ) | $ | (0.44 | ) | $ | (0.77 | ) | $ | (0.77 | ) | ||||
Weighted average common shares outstanding - basic and diluted | 17,945,995 | 14,974,953 | 17,908,349 | 14,650,608 | ||||||||||||
COMPREHENSIVE LOSS | ||||||||||||||||
Net loss | $ | (6,838 | ) | $ | (6,655 | ) | $ | (13,741 | ) | $ | (11,211 | ) | ||||
Other comprehensive loss - foreign currency translation | (757 | ) | (62 | ) | (702 | ) | (61 | ) | ||||||||
Total comprehensive loss | $ | (7,595 | ) | $ | (6,717 | ) | $ | (14,443 | ) | $ | (11,272 | ) | ||||
INMUNE BIO, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
FOR THE QUARTERS ENDED JUNE 30, 2022 AND 2021 | ||||||||
(In thousands) | ||||||||
(Unaudited) | ||||||||
For the Six Months EndedJune 30, | ||||||||
2022 | 2021 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (13,741 | ) | $ | (11,211 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation | 3,422 | 1,668 | ||||||
Accretion of debt discount | 113 | 16 | ||||||
Changes in operating assets and liabilities: | ||||||||
Research and development tax credit receivable | (13 | ) | (1,382 | ) | ||||
Other tax receivable | 457 | 62 | ||||||
Prepaid expenses | (1,944 | ) | (1,175 | ) | ||||
Prepaid expenses – related party | (37 | ) | (15 | ) | ||||
Accounts payable and accrued liabilities | (2,046 | ) | 843 | |||||
Accounts payable and accrued liabilities – related parties | (71 | ) | (25 | ) | ||||
Deferred liabilities | 2 | 393 | ||||||
Accrued liability – long-term | 176 | 24 | ||||||
Operating lease liabilities | 58 | 1 | ||||||
Net cash used in operating activities | (13,624 | ) | (10,801 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Cash paid to Xencor to settle warrant for acquired research and development intangible assets | - | (15,000 | ) | |||||
Net cash used in investing activities | - | (15,000 | ) | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Net proceeds from sale of common stock | 699 | 28,446 | ||||||
Net proceeds from the exercise of warrants | 30 | 18 | ||||||
Net proceeds from the issuance of debt | - | 14,951 | ||||||
Net cash provided by financing activities | 729 | 43,415 | ||||||
Impact on cash from foreign currency translation | (702 | ) | (61 | ) | ||||
NET (DECREASE) INCREASE IN CASH | (13,597 | ) | 17,553 | |||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 74,810 | 21,967 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 61,213 | $ | 39,520 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: | ||||||||
Cash paid for income taxes | $ | - | $ | - | ||||
Cash paid for interest expense | $ | 601 | $ | - | ||||
NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
Common stock issued to Xencor to settle warrant issued for acquired research and development intangible assets | $ | - | $ | 3,300 | ||||
Warrants issued as debt inducement | $ | - | $ | 619 | ||||
1 Year INmune Bio Chart |
1 Month INmune Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions